Clinical Trials

The Palm Beach Cancer Institute actively participates in clinical research studies involving investigational drugs and treatment protocols, allowing its patients to gain access to innovative therapies. Current research studies include treatments for ovarian cancer, metastatic colon cancer, breast cancer, lung cancer, lymphoma and melanoma. PBCI engages in National Cancer Institute-sponsored trials through the Cancer and Leukemia Group B as an affiliate of Duke University, and participates in pharmaceutical and drug development research that offers protocols for a variety of diseases.

Choosing to participate in a clinical trial is an important personal decision. To learn some general information (FAQs) about clinical trials, click here. To learn more about the clinical trials offered at the Palm Beach Cancer Institute, please click on the links below or contact the Research Nurse at 561-366-4128.

Breast Cancer:
DCRO-BR-2006-01 - A Phase II Study of Abraxane, Carboplatin and Bevacizumab in “Triple Negative” (Demonstrating No Expression For Estrogen, Progesterone or HER2 Receptors) Metastatic Breast Cancer Patients

DCRO-BR-2006-02/BMS CA180089 - A Phase II Trial of Dasatinib to Treat Women With Stage IV or Inoperable Stage III Advanced Breast Cancer

BETH (CIRG 011/NSABP B-44) - A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab.

SNDX-275-0301 - A Phase 2, Randomized, Double-Blind, Multicenter Study of Exemestane With and Without SNDX-275 in Postmenopausal Women with Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer, Progressing on Treatment with a Non-Steroidal Aromatase Inhibitor

CRAD001J2301 - A Randomized, Phase III, Double-Blind, Placebo-Controlled Multicenter of Everolimus in Combination with Trastuzumab and Paclitaxel, As First Line Therapy In Women With Her2 Positive Locally Advanced or Metastatic Breast Cancer

CRAD001Y2301 - A Randomized, Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer who are refractory to Letrozole or Anastrozole

3144A2-3003-WW - A Randomized, Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine for the Treatment of ErbB-2-Positive Locally Advanced or Metastatic Breast Cancer

Colon — Gastro-Intestinal:
New clinical trial coming soon

Endometrial:
New clinical trial coming soon

Hematologic:
New clinical trial coming soon

Lung:
CA196-005 - A Randomized Double Blind Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology

TOP 0703 - A Phase II Prospective Study Evaluating the Role of Directed Cisplatin Based Chemotherapy with Either Vinorelbine or Pemetrexed for the Adjuvant Treatment of Early Stage Non-small Cell Lung Cancer (NSCLC) in Patients Using Genomic Expression Profiles of Chemotherapy Sensitivity to Guide Therapy

Lymphoma:
New clinical trial coming soon

Melanoma:
BioVex 005/05 - A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment with OncoVEX GM-CSF Compared to Subcutaneously Administered GM-CSF in Previously Treated Melanoma Patients with Unresectable Stage IIIb, IIIc and IV Disease

H8K-MC-JZAO - A Randomized Phase III Study of Tasisulam Administered as an Intravenous Infusion on Day 1 of a 28 Day Cycle vs. Paclitaxel as Second-line Treatment in Patients with Unresectable or Metastatic Melanoma

Multiple Myeloma:
CC-5013-MM-020 - A Phase III, Randomized, Open-Label, 3-Arm Study To Determine The Efficacy And Safety Of Lenalidomide (Revlimid®) Plus Low-Dose Dexamethasone When Given Until Progressive Disease Or For 18 Four-Week Cycles Versus The Combination Of Melphalan, Prednisone, And Thalidomide Given For 12 Six-Week Cycles In Patients With Previously Untreated Multiple Myeloma Who Are Either 65 Years Of Age Or Older Or Not Candidates For Stem Cell Transplantation

Ovarian:
MORAb-003-004 - A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-sensitive Ovarian Cancer in First Relapse

Prostate:
AFFIRM–MDV3100 - A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy